Regulatory implications of ctDNA in immuno-oncology for solid tumors

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Precision oncology increasingly utilizes circulating tumor DNA (ctDNA) for minimally invasive cancer diagnosis and management.
• FDA approvals of ctDNA-based companion diagnostics support targeted and immuno-oncology therapies.
• ctDNA is vital for detecting molecular residual disease (MRD) in early-stage solid tumors to guide adjuvant or escalated treatment and prevent metastasis.

Purpose of the Study:

• To review the emerging role of ctDNA in precision oncology.
• To highlight ctDNA's application in detecting MRD for early-stage cancers.
• To discuss ctDNA's use in clinical trial enrichment and patient stratification.

Main Methods:

• Literature review of ctDNA applications in oncology.
• Analysis of FDA-approved ctDNA assays.
• Examination of ctDNA's role in MRD detection and clinical trial design.

Main Results:

• ctDNA assays are approved for targeted therapies and under development for immuno-oncology.
• ctDNA is important for MRD detection in early-stage solid tumors, guiding treatment decisions.
• Clinical trials are increasingly using ctDNA MRD for patient selection and stratification to enhance efficiency.

Conclusions:

• Further standardization and clinical validation of ctDNA assays are required.
• ctDNA shows promise as a prognostic and predictive biomarker.
• Establishing ctDNA as an efficacy-response biomarker is essential for regulatory decision-making.